Dengue and yellow fever - Challenges for the development and use of vaccines

New England Journal of Medicine

Volumn 357, Issue 22, 2007, Pages 2222-2225

  Monath, Thomas P ^a,b  

^a Kleiner Perkins Caufield & Byers   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE; LIVE VACCINE; YELLOW FEVER VACCINE;

CLINICAL FEATURE; CLINICAL TRIAL; DENGUE; DISEASE TRANSMISSION; FATALITY; HEALTH CARE POLICY; HUMAN; IMMUNE RESPONSE; IMMUNITY; INCIDENCE; INFECTION PREVENTION; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; SHORT SURVEY; VACCINATION; VIRUS TRANSMISSION; YELLOW FEVER;

EID: 36549054066     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMp0707161     Document Type: Article

References (5)

1. Gubler DJ. Dengue and dengue hemorrhagic fever: history and current status. In: Novartis Foundation. New treatment strategies for dengue and other flaviviral diseases. Chichester, United Kingdom: John Wiley, 2006:3-22.
2. Kuhn RJ, Zhang W, Rossmann MG, et al. Structure of dengue virus: implications for flavivirus organization, maturation, and cell fusion. Cell 2002;108:717-25.
3. Halstead SB. Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenic cascade. Rev Infect Dis 1989;11:Suppl 4:S830-S839.
4. Edelman R. Dengue vaccines: approach to the finish line. Clin Infect Dis 2007;45:Suppl 1:S56-S60.
5. Monath TP, Teuwen D, Cetron MS. Yellow fever. In: Plotkin S, Orenstein W, eds. Vaccines. 4th ed. Philadelphia: Saunders (in press).